Skip to main content

Bifidobacterium animalis subsp. lactis BL-99 ameliorates colitis-related lung injury in mice by modulating short-chain fatty acid production and inflammatory monocytes/macrophages.

  • 2023
  • Food & Function 14(2)
    • Xin Nan
    • Wen Zhao
    • Wei-Hsien Liu
    • Yalan Li
    • Na Li
    • Yanfei Hong
    • Jiaqi Cui
    • Xuekai Shang
    • Haotian Feng
    • W. Hung
    • Guiying Peng

Abstract

Pulmonary inflammation as one of the extraintestinal manifestations of ulcerative colitis (UC) has attracted extensive attention, and its pathogenesis is closely related to gut dysbiosis. Bifidobacterium animalis subsp. lactis BL-99 (BL-99) can alleviate osteoporosis caused by UC, but less research has been done on other extraintestinal manifestations (EIM) caused by UC. This study aimed to explore the role and potential mechanisms of BL-99 on DSS-induced pulmonary complications in colitis mice. The results showed that BL-99 decreased weight loss, disease activity index score, colonic pathology score, and the production of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, and IL-6) in colitis mice. BL-99 also alleviated DSS-induced lung pathological damage by suppressing the infiltration of pro-inflammatory cytokines, inflammatory monocytes, and macrophages. Furthermore, 16S rRNA gene sequencing showed lower abundances of several potentially pathogenic bacteria (e.g., Burkholderia, Shigella, and Clostridium perfringens) and enrichment in specific beneficial bacteria (e.g., Adlercreutzia and Bifidobacterium animalis) in colitis mice with BL-99 treatment. Targeted metabolomics suggested that BL-99 intervention promoted the production of intestinal acetate and butyrate. Finally, we observed that the pulmonary expression of primary acetate and butyrate receptors, including FFAR2, FFAR3, and, GPR109a, was up-regulated in BL-99-treated mice, which negatively correlated with inflammatory monocytes and macrophages. Altogether, these results suggest that BL-99 might be utilized as a probiotic intervention to prevent the incidence of colitis-related lung injury owing to its ability to shape the intestinal microbiota and suppress inflammation.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium lactis BL818Improved Disease Activity Index ScoreBeneficial
Large
Bifidobacterium lactis BL818Improved DSS-Induced Lung Pathological DamageBeneficial
Moderate
Bifidobacterium lactis BL818Increased Beneficial Gut BacteriaBeneficial
Moderate
Bifidobacterium lactis BL818Reduced Colonic PathologyBeneficial
Large
Bifidobacterium lactis BL818Reduced Potential Pathogenic BacteriaBeneficial
Moderate
Bifidobacterium lactis BL818Reduced Proinflammatory Cytokine ProductionBeneficial
Large
Bifidobacterium lactis BL818Reduced Weight Loss in Colitis MiceBeneficial
Moderate
⬆ Back to top
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.
Receive updates about our products, services, sales, and special offers. Unsubscribe anytime. See our Privacy Policy for details on how we handle your information.

Join Our Community

Use support@pillser.com to get in touch.